Jefferies analyst Michael Yee notes that Biohaven’s (BHVN) Phase 3 study of taldefgrobep alfa failed on the primary endpoint with no statistical separation versus placebo on the primary endpoint of MFM-32 at 48 weeks. Following the competitor data, Scholar Rock (SRRK) is now “a more derisked cleaner story and easier to own,” says the analyst, who reiterates a Buy rating and $50 price target on Scholar Rock shares ahead of obesity proof of concept data due in Q2 of 2025 and the SMA launch planned for Q4 of 2025.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRRK: